论文部分内容阅读
目的探讨尤瑞克林联合依达拉奉治疗急性脑梗死的疗效及安全性。方法收集巩义市瑞康医院收治的急性脑梗死患者88例,随机分为观察组和对照组,每组44例,对照组在常规治疗基础上给予依达拉奉治疗,观察组在对照组治疗基础上给予尤瑞克林治疗,观察两组治疗前后神经功能损伤(NIHSS)及日常生活能力评定(ADL)评分、治疗期不良反应,治疗14 d后疗效。结果观察组治疗后NIHSS及ADL评分均低于同组治疗前及对照组治疗后(P<0.05),总有效率高于对照组(P<0.05),两组不良反应发生率比较差异未见统计学意义(P>0.05)。结论尤瑞克林联合依达拉奉治疗急性脑梗死可有效改善患者日常生活功能及神经功能缺损,且不增加不良反应,值得临床推广。
Objective To investigate the efficacy and safety of uracil combined with edaravone in the treatment of acute cerebral infarction. Methods 88 patients with acute cerebral infarction admitted to Ruigang Hospital of Gongyi City were randomly divided into observation group and control group, 44 cases in each group. The control group was treated with edaravone on the basis of routine treatment, while the observation group was treated in control group Based on the treatment of ureclin, the NIHSS and ADL scores of the two groups were observed before and after treatment. The adverse reactions during the treatment period and the therapeutic effect after 14 days of treatment were observed. Results The scores of NIHSS and ADL in the observation group were lower than those of the control group before and after treatment (P <0.05), and the total effective rate was higher than that of the control group (P <0.05). There was no significant difference between the two groups in the incidence of adverse reactions Statistical significance (P> 0.05). Conclusion The combination of erilecin and edaravone in the treatment of acute cerebral infarction can effectively improve patients’ daily life function and neurological deficit without increasing adverse reactions and is worthy of clinical promotion.